HR LOW-POSITIVE/HER2-NEGATIVE BREAST NEOPLASMS

Clinical trials for HR LOW-POSITIVE/HER2-NEGATIVE BREAST NEOPLASMS explained in plain language.

Never miss a new study

Get alerted when new HR LOW-POSITIVE/HER2-NEGATIVE BREAST NEOPLASMS trials appear

Sign up with your email to follow new studies for HR LOW-POSITIVE/HER2-NEGATIVE BREAST NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Major trial tests promising new drug combo to shrink tumors before breast cancer surgery

Disease control Recruiting now

This large study is testing whether adding a new targeted drug called sacituzumab tirumotecan to standard chemotherapy and immunotherapy works better before surgery for certain aggressive, early-stage breast cancers. Researchers want to see if this three-drug combination helps el…

Matched conditions: HR LOW-POSITIVE/HER2-NEGATIVE BREAST NEOPLASMS

Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control

Last updated Mar 30, 2026 14:30 UTC

HR LOW-POSITIVE/HER2-NEGATIVE BREAST NEOPLASMS

Get alerted when new HR LOW-POSITIVE/HER2-NEGATIVE BREAST NEOPLASMS trials appear

Major trial tests promising new drug combo to shrink tumors before breast cancer surgery